Tazorac (tazarotene) Gel 0.05%, 15 x 3.5g, sample packs, Allergan Inc, Irvine, CA 92612…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Recalling firm

Allergan Sales, LLC

Origin

TX, United States

Initiated by

Voluntary: Firm initiated

FDA recall number

D-1065-2016

Other Tazarotene recalls

See all

Class III · Low risk Terminated Mar 21, 2018

Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-295-10.

Reason Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.

Mayne Pharma Inc NDC 51862-295-10 D-0616-2018

Class II · Moderate risk Terminated Jun 30, 2016

TAZORAC (tazarotene) Gel 0.05%, Rx only, packaged in 15 x 3.5 g professional sample containers, Manufactured by: Allergan Inc…

Reason Failed Content Uniformity Specifications

Allergan Sales, LLC D-0100-2017

Class II · Moderate risk Terminated Jun 30, 2016

TAZORAC (tazarotene) Gel 0.05%, Rx only, For Dermatologic Use Only, Not for Ophthalmic Use, packaged in a) 30 g tubes (NDC…

Reason Failed Content Uniformity Specifications

Allergan Sales, LLC D-0099-2017

Class II · Moderate risk Terminated May 10, 2016

Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) and b) 100g (NDC 0023-8335-10) tubes, Allergan…

Reason Failed Content Uniformity Specifications.

Allergan Sales, LLC NDC 0023-8335-03 D-1064-2016